Wynnefield Capital Stake in Neptune Tech & Bioressources (NEPT) Cut by $800,000; Suffolk Capital Management Stake in Sage Theraputics (SAGE) Increased by $7.82 Million as Stock Declined

May 21, 2018 - By Winifred Garcia

Sage Therapeutics, Inc. (NASDAQ:SAGE) Logo

Suffolk Capital Management Llc increased its stake in Sage Theraputics Inc (SAGE) by 307.3% based on its latest 2017Q4 regulatory filing with the SEC. Suffolk Capital Management Llc bought 47,665 shares as the company’s stock declined 6.84% with the market. The institutional investor held 63,176 shares of the health care company at the end of 2017Q4, valued at $10.41M, up from 15,511 at the end of the previous reported quarter. Suffolk Capital Management Llc who had been investing in Sage Theraputics Inc for a number of months, seems to be bullish on the $7.64 billion market cap company. The stock decreased 0.79% or $1.3 during the last trading session, reaching $164.26. About 346,610 shares traded. Sage Therapeutics, Inc. (NASDAQ:SAGE) has risen 135.95% since May 21, 2017 and is uptrending. It has outperformed by 124.40% the S&P500.

Nelson Obus decreased its stake in Neptune Tech & Bioressources (NEPT) by 28.57% based on its latest 2017Q4 regulatory filing with the SEC. Wynnefield Capital Inc sold 400,000 shares as the company’s stock rose 43.43% while stock markets declined. The hedge fund run by Nelson Obus held 1.00 million shares of the major pharmaceuticals company at the end of 2017Q4, valued at $2.36M, down from 1.40M at the end of the previous reported quarter. Wynnefield Capital Inc who had been investing in Neptune Tech & Bioressources for a number of months, seems to be less bullish one the $230.24M market cap company. The stock decreased 1.36% or $0.04 during the last trading session, reaching $2.91. About 269,745 shares traded. Neptune Technologies & Bioressources Inc. (NASDAQ:NEPT) has risen 173.08% since May 21, 2017 and is uptrending. It has outperformed by 161.53% the S&P500.

Investors sentiment increased to 1.49 in Q4 2017. Its up 0.28, from 1.21 in 2017Q3. It improved, as 27 investors sold SAGE shares while 56 reduced holdings. 63 funds opened positions while 61 raised stakes. 41.45 million shares or 7.53% more from 38.55 million shares in 2017Q3 were reported. Marshall Wace Llp invested in 134,788 shares or 0.93% of the stock. Jane Street Gru Ltd Liability reported 14,872 shares or 0.01% of all its holdings. 2,942 were accumulated by First Republic Inv Management. Boothbay Fund Mngmt Lc accumulated 3,908 shares or 0.09% of the stock. 2.07M were reported by Wellington Management Group Limited Liability Partnership. 318 were reported by Global X Mgmt Co Llc. Stratos Wealth has 32 shares. Picton Mahoney Asset Mgmt stated it has 16,200 shares or 0.07% of all its holdings. Moreover, Envestnet Asset Mgmt has 0% invested in Sage Therapeutics, Inc. (NASDAQ:SAGE) for 2,624 shares. Us State Bank De has invested 0% in Sage Therapeutics, Inc. (NASDAQ:SAGE). California Public Employees Retirement System has invested 0.02% of its portfolio in Sage Therapeutics, Inc. (NASDAQ:SAGE). Nuveen Asset Mngmt holds 0.01% of its portfolio in Sage Therapeutics, Inc. (NASDAQ:SAGE) for 8,814 shares. Brown Advisory has invested 0% of its portfolio in Sage Therapeutics, Inc. (NASDAQ:SAGE). Brinker holds 0.02% or 2,447 shares. Fund Management Sa holds 3,065 shares.

Among 18 analysts covering SAGE Therapeutics (NASDAQ:SAGE), 16 have Buy rating, 0 Sell and 2 Hold. Therefore 89% are positive. SAGE Therapeutics had 57 analyst reports since September 3, 2015 according to SRatingsIntel. The rating was upgraded by Chardan Capital Markets to “Buy” on Thursday, December 7. The firm has “Buy” rating given on Thursday, September 3 by JP Morgan. The firm earned “Buy” rating on Monday, October 16 by RBC Capital Markets. The firm has “Buy” rating by Canaccord Genuity given on Tuesday, September 12. SunTrust maintained it with “Buy” rating and $82.0 target in Thursday, October 19 report. The rating was maintained by Cowen & Co on Thursday, August 3 with “Buy”. BMO Capital Markets maintained the shares of SAGE in report on Thursday, December 7 with “Buy” rating. The firm earned “Buy” rating on Thursday, November 2 by Stifel Nicolaus. As per Thursday, August 3, the company rating was maintained by BMO Capital Markets. BMO Capital Markets maintained the shares of SAGE in report on Thursday, September 14 with “Outperform” rating.

More notable recent Sage Therapeutics, Inc. (NASDAQ:SAGE) news were published by: Businesswire.com which released: “Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)” on May 03, 2018, also Benzinga.com with their article: “Benzinga Pro’s 5 Stocks To Watch Today” published on April 23, 2018, Streetinsider.com published: “Omega’s 13F Shows Increase in Ocwen (OCN), Synchrony (SYF), United (UAL), Exits Zynga (ZNGA) (More…)” on May 15, 2018. More interesting news about Sage Therapeutics, Inc. (NASDAQ:SAGE) were released by: Bizjournals.com and their article: “Sage Therapeutics asks FDA to approve lead drug for postpartum depression” published on April 23, 2018 as well as Seekingalpha.com‘s news article titled: “Sage Therapeutics 2018 Q1 – Results – Earnings Call Slides” with publication date: May 03, 2018.

Suffolk Capital Management Llc, which manages about $1.92 billion and $770.38M US Long portfolio, decreased its stake in Integrated Devices (NASDAQ:IDTI) by 15,070 shares to 31,096 shares, valued at $924,000 in 2017Q4, according to the filing. It also reduced its holding in Xylem Inc. (NYSE:XYL) by 31,134 shares in the quarter, leaving it with 186,751 shares, and cut its stake in Covanta Holding Corp. (NYSE:CVA).

Since December 14, 2017, it had 0 insider buys, and 6 insider sales for $42.42 million activity. PAUL STEVEN M sold $10.00 million worth of stock or 58,139 shares. Another trade for 28,153 shares valued at $4.02M was made by IGUCHI KIMI on Monday, April 23. The insider Kanes Stephen sold $7.80 million. The insider Robichaud Albert sold 60,000 shares worth $9.57M. On Tuesday, April 17 STARR KEVIN P sold $9.96M worth of Sage Therapeutics, Inc. (NASDAQ:SAGE) or 59,000 shares.

Neptune Technologies & Bioressources Inc. (NASDAQ:NEPT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Winifred Garcia

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:








Recent Posts